Ray Therapeutics closes $6M seed financing to advance novel optogenetics platform to treat blinding diseases
Top-tier advanced therapies investor 4BIO Capital led the financing round.
The financing will be used to advance its lead optogenetics gene therapy Ray-001 into clinical trials for retinitis pigmentosa.